Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22520631 | 0.92 | HRH3 (0.35) | HRH3OPRM1OPRL1CYP2D6TLR9 | |
| SCHEMBL22565135 | 0.87 | NCF1 (0.42) | HRH3NCF1OPRM1OPRL1CACNA2D1 | |
| SCHEMBL27307184 | 0.86 | OPRM1 (0.38) | HRH3NCF1OPRM1OPRL1CACNA2D1 | |
| SCHEMBL24475333 | 0.86 | TSHR (0.36) | HRH3OPRM1OPRL1TLR9TLR8 | |
| SCHEMBL24671071 | 0.86 | OPRM1 (0.35) | HRH3OPRM1OPRL1 | |
| SCHEMBL24475297 | 0.86 | HRH3 (0.30) | HRH3 | |
| SCHEMBL27013290 | 0.86 | HRH3 (0.33) | HRH3NCF1CYP2D6 | |
| SCHEMBL27013289 | 0.86 | — | — | |
| SCHEMBL24475321 | 0.85 | HRH3 (0.32) | HRH3OPRM1OPRL1 | |
| SCHEMBL27016087 | 0.85 | HRH3 (0.32) | HRH3OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022253250-A1 | BRUTON'S TYROSINE KINASE DEGRADER CONTAINING FUSED-RING OR SPIRO-RING | 正大天晴药业集团股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | HRH3 1546/4885NCF1 4170/4885OPRM1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.